Development of antiangiogenic agents for ovarian cancer

Expert Review of Anticancer Therapy

Volumn 8, Issue 1, 2008, Pages 21-32

  Collinson, Fiona J ^a   Hall, Geoff D ^a   Perren, Timothy J ^a   Jayson, Gordon C ^b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Angiogenesis; Bevacizumab; Ovarian cancer; Targeted therapy; VEGF

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIBF 1120; CARBOPLATIN; CEDIRANIB; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; ENZASTAURIN; ERLOTINIB; GEMCITABINE; HYBRID PROTEIN; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PERTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; THALIDOMIDE; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VEGF TRAP;

BLEEDING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER SURGERY; CARCINOGENESIS; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIGESTIVE SYSTEM PERFORATION; DRUG DESIGN; DRUG RESPONSE; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPERTENSION; LEUKOENCEPHALOPATHY; LOW DRUG DOSE; LUNG EMBOLISM; MAINTENANCE THERAPY; MONOTHERAPY; MORBIDITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PAIN; PROGNOSIS; PROTEINURIA; REVIEW; TRACHEOESOPHAGEAL FISTULA; TUMOR VASCULARIZATION; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT; FEMALE; NEOVASCULARIZATION (PATHOLOGY); OVARY TUMOR; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS;

EID: 38349078505     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.1.21     Document Type: Review

References (114)

1. Harries M, Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol. 3(9), 529-536 (2002).
2. Cannistra SA. Cancer of the ovary. N. Engl. J. Med. 351(24), 2519-2529 (2004).
3. ICON3 Collaborators. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360(9332), 505-515 (2002).
4. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334(1), 1-6 (1996).
5. Muggia F, Braly P, Brady M. Randomised Phase III trial study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynaecologic Oncology Group study. J. Clin. Oncol. 18(1), 106-115 (2000).
6. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl Cancer Inst. 92(9), 699-708 (2000).
7. Darcy K, Schilder RJ. Relevant molecular markers and targets. Gynecol-Oncol. 103, S6-S13 (2006).
8. Agarwal R, Linch M, Kaye SB. Novel therapeutic agents in ovarian cancer. Eur. J. Surg. Oncol. 32(8), 875-886 (2006).
9. Bhoola SM, Alvarez RD. Novel therapies for recurrent ovarian cancer management. Expert Rev. Anticancer Ther. 4(3), 437-448 (2004).
10. See HT, Kavanagh JJ. Novel agents in epithelial ovarian cancer. Cancer Invest. 22(Suppl. 2), 29-44 (2004).
11. Martin L, Schilder RJ. Novel non-cytotoxic therapy in ovarian cancer: current status and future prospects. J Natl. Compr. Cancer Netw. 4(9), 955-966 (2006).
12. Ausprunk DH, Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc. Res. 14(6), 53-65 (1977).
13. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. 175(3), 409-416 (1972).
14. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 82(1), 4-6 (1990).
15. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706), 58-62 (2005).
16. Martin L, Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin. Oncol. 25(20). 2894-2901 (2007).
17. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23(5), 1011-1027 (2005).
18. Ferrara N, Gerber H, LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9, 669-676 (2003).
19. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endotheliai growth factor is a secreted angiogenic mitogen. Science 246(4935), 1306-1309 (1989).
20. Senger DR, Galli SJ, Dvorak AM et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219(4587), 983-985 (1983).
21. Tischer E, Mitchell R, Hartman T et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266(18), 11947-11954 (1991).
22. Bates DO, Harper SJ. Therapeutic potential of inhibitory VEGF splice variants. Future Oncol. 1(4), 467-473 (2005).
23. Woolard J, Wang WY, Bevan HS et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64(21), 7822-7835 (2004).
24. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20(21), 4368-4380 (2002).
25. Shweiki D, Itin A, Soffer D et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359(6398), 843-845 (1992).
26. Hasan J, Jayson GC. VEGF antagonists. Expert Opin. Biol. Ther. 1(4), 703-718 (2001).
27. Ferrara N. Vascular endothelial growth factor. Eur. J. Cancer 32A(14), 2413-2422 (1996).
28. Larrivee B, Karsan A. Signaling pathways induced by vascular endothelial growth factor (review). Int. J. Mol. Med. 5(5), 447-456 (2000).
29. Shibuya M, Yamaguchi S, Yamane A et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5(4), 519-524 (1990).
30. Terman BI, Carrion ME, Kovacs E et al. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6(9), 1677-1683 (1991).
31. Millauer B, Wizigmann-Voos S, Schnurch H et al. High affinity VEGF binding and developmental expression suggest FLK-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72, 835-846 (1993).
32. Soker S, Fidder H, Neufeld G, Klagsbrun M. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J. Biol. Chem. 271(10), 5761-5767 (1996).
33. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/ vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146(5), 1029-1039 (1995).
34. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18(1), 4-25 (1997).
35. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103(2), 159-165 (1999).
36. Watanabe Y, Lee SW, Detmar M, Ajioka I, Dvorak HF. Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells. Oncogene 14(17), 2025-2032 (1997).
37. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc. Res. 49, 568-581 (2001).
38. Alon T, Hemo, I, Itin A et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1, 1024-1028 (1995).
39. Zebrowski BK, Liu W, Ramirez K et al. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann. Surg. Oncol. 6(4), 373-378 (1999).
40. Yoshiji H, Kuriyama S, Hicklin DJ et al. The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. Hepatology 33(4), 841-847 (2001).
41. Yuan F, Chen Y, Dellian M et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/ vascular permeability factor antibody. Proc. Natl. Acad. Sci. USA 93(25), 14765-14770 (1996).
42. Shaheen RM, Ahmad SA, Liu W et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br. J. Cancer 85(4), 584-589 (2001).
43. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer 2(11), 826-835 (2002).
44. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10(2), 145-147 (2004).
45. Shaked Y, Bertolini F, Man S et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7(1), 101-111 (2005).
46. Beaudry P, Force J, Naumov GN et al. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin. Cancer Res. 11(9), 3514-3522 (2005).
47. Yoneda J, Kuniyasu H, Crispens MA et al. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J. Natl Cancer Inst. 90(6), 447-454 (1998).
48. Ramakrishnan S, Subranianian IV, Yokoyama Y. Geller M. Angiogenesis in normal and neoplastic ovaries. Angiogenesis 8(2), 169-182 (2005).
49. Fraser HM, Wilson H, Wulff C, Rudge JS, Wiegand SJ. Administration of vascular endothetial growth factor Trap during the 'post-angiogenic' period of the luteal phase causes rapid functional luteolysis and selective endothelial cell death in the marmoset. Reproduction 132(4), 589-600 (2006).
50. Abulafia O, Sherer DM. Angiogenesis of the ovary. Am. J. Obstet. Gynecol. 182(1 Pt 1), 240-246 (2000).
51. Schumacher JJ, Dings RP, Cosin J et al. Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer Res. 67(8), 3683-3690 (2007).
52. Gadducci A, Ferrero A, Cosio S et al. Intratumoral microvessel density in advanced epithelial ovarian cancer and its use as a prognostic variable. Anticancer Res. 26(5B), 3925-3932 (2006).
53. Raspollini MR, Amunni G, Villanucci A et al. Prognostic significance of microvessel density and vascular enclothelial growth factor expression in advanced ovarian serous carcinoma. Int. J. Gynecol. Cancer 14(5), 815-823 (2004).
54. Gasparini G, Bonoldi E, Viale G et al. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int. J. Cancer 69(3), 205-211 (1996).
55. Zhang A, Meng L, Wang Q et al. Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2. Oncol. Rep. 15(4), 831-836 (2006).
56. Huang S, Robinson JB, Deguzman A, Bucana CD, Fidler IJ. Blockade of nuclear factor-κB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 60(19), 5334-5339 (2000).
57. Yukita A, Asano M, Okamoto T, Mizutani S, Suzuki H. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo. Anticancer Res. 20(1A), 155-160 (2000).
58. Byrne AT, Ross L, Holash J et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin. Cancer Res. 9(15), 5721-5728 (2003).
59. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am. J Pathol. 153(4), 1249-1256 (1998).
60. Hu L, Hofmann J. Holash J et al. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin. Cancer Res. 11 (19 Pt 1), 6966-6971 (2005).
61. Thaker PH, Yazici S, Nilsson MB et al. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin. Cancer Res. 11 (13), 4923-4933 (2005).
62. Pourgholami MH, Yan Cai Z, Lu Y, Wang L, Morris DL. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin. Cancer Res. 12(6), 1928-1935 (2006).
63. Garofalo A, Naumova E, Manenti L et al. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin. Cancer Res. 9(9), 3476-3485 (2003).
64. Paley PJ, Staskus KA, Gebhard K et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80(1), 98-106 (1997).
65. Alvarez AA, Krigman HR, Whitaker RS, Dodge RK, Rodriguez GC. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin. Cancer Res. 5(3), 587-591 (1999).
66. Cooper BC, Ritchie JM, Broghammer CL et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin. Cancer Res. 8(10), 3193-3197 (2002).
67. Yamamoto S, Konishi I, Mandai M et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br. J. Cancer 76(9), 1221-1227 (1997).
68. Kerbel RS, Yu J, Tran J et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. 20(1-2), 79-86 (2001).
69. Huang J, Soffer SZ, Kim ES et al. Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol. Cancer Res. 2(1), 36-42 (2004).
70. Wildiers H, Guetens G, De Boeck G et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br. J. Cancer 88(12), 1979-1986 (2003).
71. Borgstrom P, Gold DP, Hillan KJ, Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res. 19(5B), 4203-4214 (1999).
72. Teicher BA, Sotomayor EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 52(23), 6702-6704 (1992).
73. Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin. Oncol. 23(6), 1295-1311 (2005).
74. Giavazzi R, Garofalo A, Ferri C et al. Batimastat, a synthetic inhibitor of matrix mcualloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin. Cancer Res. 4(4), 985-992 (1998).
75. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004).
76. Giantonio, BJ, Levy DE, O'Dwyer FJ et al. A Phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann. Oncol. 17(9), 1399-1403 (2006).
77. Kabbinavar FF, Hambleton J, Mass RD et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J. Clin. Oncol. 23(16), 3706-3712 (2005).
78. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542-2550 (2006).
79. Miller K, Wang M, Gralow J et al. First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: a randomized, Phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100). Eur. J. Cancer Suppl. 3(77), (2005) (Abstract 275).
80. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57(20), 4593-4599 (1997).
81. Kabbinavar FF, Wong JT, Ayala RE et al. The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice. Proc. Am. Cancer Res. 36, 488 (1995) (Abstract).
82. Miller KD, Chap LI, Holmes FA et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Chn. Oncol. 23(4), 792-799 (2005).
83. Kabbinavar F, Schulz J, McCleod M. Bevacizumab (a monoclonal agent to vascular endothelial growth factor) to prolong progression free survival in first line colorectal carcinoma in patients who are not suitable for first line CPT-11 (study AVF2192g). Am. Soc. Clin. Oncol. 23, 249 (2004) (Abstract 3516).
84. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. 25(33), 5165-5171 (2007).
85. Garcia A, Hirte H, Fleming G et al. Interim report of Phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma (PPC): a California Cancer Consortium Trial. J. Clin. Oncol. 23(16S) (2005) (Abstract 5000).
86. Penson RT, Cannistra SA, Seiden CN et al. Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced mullerian tumours. J. Clin. Oncol. 24(16S) (2006) (Abstract 5020).
87. Freiberg G, Oza A, Morgan A et al. Bevacizumab plus erlotinib for patients with recurrent ovarian and fallopian tube cancer. J. Clin. Oncol. 24 (16S) (2006) (Abstract 5018).
88. Cannistra SA, Matulonis U, Penson R et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. J. Clin. Oncol.24(16S) (2006) (Abstract 5006).
89. Simpkins F. Belinson JL, Rose PG. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol. Oncol. 107(1), 118-123 (2007).
90. Verheul HM, Hoekman K, Jorna AS, Smit EF, Pinedo HM. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist 5(Suppl. 1), 45-50 (2000).
91. Numnum TM, Rocconi RP, Whitworth J, Barnes MN. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol. Oncol. 102(3), 425-428 (2006).
92. Tamsma JT, Keizer HJ, Meinders AE. Pathogenesis of malignant ascires: Starling's law of capillary hemodynamics revisited. Ann. Oncol. 12(10), 1353-1357 (2001).
93. Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol. Oncol. 102(2), 140-144 (2006).
94. Cohn DE, Valmadre S, Resnick KE et al. Bevacizumab and weekly raxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol. Oncol. 102(2), 134-139 (2006).
95. Wild R, Dings RE Subramanian I, Ramakrishnan S. Carboplatin selectively induces the VEGF stress response in endothelial cells: potentiation of antitumor activity by combination treatment with antibody to-VEGF. Int. J. Cancer 110(3), 343-351 (2004).
96. Investigator Brochure: Bevacizumab (version 15) Hoffman La-Roche Ltd, NJ, USA (2007).
97. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events inpatients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl Cancer Inst. 99(16), 1232-1239 (2007).
98. Tew W, Colombo N, Ray-Caquard I et al. VEGF-Trap for patients with recurrent platinum resistant epithelial ovarian cancer. J. Clin. Oncol. 25(18S) (2007) (Abstract 5508).
99. Mavria G, Vercoulen Y, Yeo M et al. ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell 9(1), 33-44 (2006).
100. Welch S, Hirte H, Schildlder R et al. Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: a PMH Phase II consortium trial. J. Clin. Oncol. 24(18S) (2006) (Abstract 5084).
101. Azad N, Posadas E, Kwitkowski V et al. Increased efficacy and toxicity with combinition anti-VEGF therapy using sorafenib and bevacizumab. J. Clin. Oncol. 24(18S) (2006) (Abstract 3004).
102. Maihle NJ, Baron AT, Barrette BA et al. EGF/ErbB receptor family in ovarian cancer. Cancer Treat. Res. 107, 247-258 (2002).
103. Riedel E Gotte K, Li M, Hormann K, Grandis JR. EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration. Int. J. Oncol. 21(1), 11-16 (2002).
104. Viloria-Petit A, Crombet T, Jothy S et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 61(13), 5090-5101 (2001).
105. Laughner E, Taghavi P, Chiles K, Malion PC, Semenza GL. HER2 (neu) signaling increases the rare of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell Biol. 21(12), 3995-4004 (2001).
106. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a Phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21(2), 283-290 (2003).
107. Gordon MS, Matei D, Aghajanian C et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J. Clin. Oncol. 24(26), 4324-4332 (2006).
108. Makhija S, Glenn D, Ueland F et al. Results from a Phase II randomised, placebo-controlled, double-blindtrial suggests improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum resistant ovarian, fallopian tube, or primary peritoneal cancer. J. Clin. Oncol. 25(18S) (2007) (Abstract 5507).
109. Testa JR, Tsichlis PN. AKT signaling in normal and malignant cells. Oncogene 24(50), 7391-7393 (2005).
110. Hudson CC, Liu M, Chiang GG et al. Regulation of hypoxia-inducible factor 1 α expression and function by the mammalian target of rapamycin. Mol. Cell Biol. 22(20), 7004-7014 (2002).
111. Shaked Y, Bocci G, Munoz R et al. Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. Curr Cancer Drug Targets 5(7), 551-559 (2005).
112. Gutman S, Kessler LG. The WS Food and Drug Administration perspective on cancer biomarker development. Nat. Rev. Cancer 6(7), 565-571 (2006).
113. Bookman MA for the Gynecologic Cancer InterGroup (GCIG) through the Gynecologic Oncology Group (GOG): GOGO 182-ICON5: 5-arm Phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-liposomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithehal ovarian (EOC) or primary peritoneal (PPC) carcinoma. J. Clin. Oncol. 24(Suppl. 456), (2006) (Abstract 5002).
114. Schultheis A, Yang D, Garcia AA et al. Angiogenesis pathway gene polymorphisms associated with clinical outcome in recurrent ovarian cancer treated with low dose cyclophosphamide and bevacizumab: A Californian Consortium Trial. J. Clin. Oncol. 24(18S) (2006) (Abstract 5017).